COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

Sponsor
Dr Gerry Gin Wai Kwok
Study ID
NCT04356508
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.

Key Dates

Start date
Apr 14, 2020
Status verified
Apr 2020
Primary completion
Jun 30, 2020
Completion
Aug 31, 2021

Study Design

Enrollment
15 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention (n=10)
    Nivolumab + best supportive care
  • No Intervention: Non-intervention (n=5)
    Best supportive care

Primary Outcome Measure

Viral clearance kinetics [ Time Frame: From diagnosis to recovery, assessed up to 6 months ]

Central Contacts

Related Studies